Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.34 |
| ▸ | CAMKK1 | Q8N5S9 | 3/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | ADH5 | P11766 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 2/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435666 | 0.94 | CREBBP (0.34) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL1290002 | 0.93 | BRD4 (0.36) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL1290218 | 0.92 | KDM4E (0.38) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL1290026 | 0.91 | HSD17B10 (0.38) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL1290198 | 0.90 | NOTUM (0.36) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL19723726 | 0.90 | KDM4E (0.34) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL1290228 | 0.90 | KDM4E (0.34) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL1290025 | 0.90 | AURKA (0.38) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL12501927 | 0.90 | ADRB3 (0.33) | KDM4EALDH1A1GAAPKMCAMKK2 | |
| SCHEMBL5422510 | 0.90 | CA9 (0.36) | KDM4EALDH1A1GAAPKMCAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2015-05-21 | — | — | US | claimed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | claimed |
| EP-2621491-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Evolva SA (CH) | 2013-08-07 | — | — | EP | claimed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | claimed |
| EP-3476844-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3476844-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2018-10-18 | — | — | US | disclosed |
| EP-2621491-B1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEV GAITHERSBURG INC (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3312176-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | disclosed |
| EP-2621491-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Evolva SA (CH) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012104305-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | KDM4E 555/4885ALDH1A1 3182/4885GAA 2095/4885 |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | DCAF15, CUL4A, CUL4B | KDM4E 518/4885ALDH1A1 3404/4885GAA 2043/4885 |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | KDM4E 1923/4885ALDH1A1 3063/4885GAA 2833/4885 |
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | KDM4E 1923/4885ALDH1A1 3063/4885GAA 2833/4885 |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | KDM4E 555/4885ALDH1A1 3182/4885GAA 2095/4885 |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | KDM4E 2480/4885ALDH1A1 3718/4885GAA 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.